UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 5 von 21
Datensatz exportieren als...
BibTeX
Cancer risk among statin users: A population‐based cohort study
International journal of cancer, 2005-04, Vol.114 (4), p.643-647
Friis, Søren
Poulsen, Aslak H.
Johnsen, Søren P.
McLaughlin, Joseph K.
Fryzek, Jon P.
Dalton, Susanne O.
Sørensen, Henrik T.
Olsen, Jørgen H.
2005
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Friis, Søren
Poulsen, Aslak H.
Johnsen, Søren P.
McLaughlin, Joseph K.
Fryzek, Jon P.
Dalton, Susanne O.
Sørensen, Henrik T.
Olsen, Jørgen H.
Titel
Cancer risk among statin users: A population‐based cohort study
Ist Teil von
International journal of cancer, 2005-04, Vol.114 (4), p.643-647
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2005
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
Hydroxymethylglutaryl‐CoA reductase inhibitors (statins) have been linked with potential chemopreventive effects; however, the data are conflicting. We conducted a population‐based cohort study using data from the Prescription Database of North Jutland County and the Danish Cancer Registry for the period 1989–2002. In a study population of 334,754 county residents, we compared overall and site‐specific cancer incidence among 12,251 statin users (≥2 prescriptions) with cancer incidence among nonusers and users of other lipid‐lowering drugs (n = 1,257). Statistical analyses were based on age‐standardization and Poisson regression analysis, adjusting for age, gender, calendar period and use of NSAIDs, hormone replacement therapy and cardiovascular drugs. We identified 398 cancer cases among statin users during a mean follow‐up period of 3.3 years (range 0–14 years). The age‐ and gender‐standardized incidence rates of cancer overall were 596 per 100,000 person‐years among statin users, 645 per 100,000 person‐years among nonusers and 795 per 100,000 person‐years among users of other lipid‐lowering drugs. Adjusted rate ratios for cancer overall among statin users were 0.86 (95% CI, 0.78–0.95) compared to nonusers and 0.73 (95% CI, 0.55–0.98) compared to users of other lipid‐lowering drugs. No significantly increased or decreased rate ratios were observed for any of the studied site‐specific cancers (liver, colorectum, lung, breast, prostate, female genital organs and lymphatic and haematopoietic tissue), but most estimates tended to be less than 1.0. Stratification by duration of follow‐up or number of prescriptions revealed no clear trends. In summary, individuals prescribed statins experienced a slightly reduced cancer incidence compared to population controls of nonusers and users of other lipid‐lowering drugs. Larger and longer‐term studies are needed to determine the potentially protective effect of statin use on cancer development. © 2004 Wiley‐Liss, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0020-7136
eISSN: 1097-0215
DOI: 10.1002/ijc.20758
Titel-ID: cdi_proquest_miscellaneous_17828108
Format
–
Schlagworte
Adult
,
Aged
,
cancer incidence
,
Cohort Studies
,
cohort study
,
epidemiology
,
Female
,
Humans
,
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
,
Incidence
,
Male
,
Middle Aged
,
Neoplasms - chemically induced
,
Neoplasms - epidemiology
,
Neoplasms - etiology
,
Registries
,
risk
,
Risk Factors
,
statins
,
Time Factors
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX